Evaluating a Multilevel Communication Campaign to Increase HIV Vaccine Trial Enrollment

评估多层次沟通活动以增加艾滋病毒疫苗试验注册人数

• 批准号: 10625227
• 负责人: Michele Peake Andrasik
• 金额: $ 65.12万
• 依托单位: FRED HUTCHINSON CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-19 至 2028-02-29
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10625227
• 关键词: Address; Advertising; Affect; Awareness; Behavioral; Black, Indigenous, People of Color; COVID-19; COVID-19 Prevention Network; COVID-19 pandemic; COVID-19 vaccine; Classification; Collaborations; Communication; Communities; Data; Development; Dissemination and Implementation; Educational Curriculum; Effectiveness; Electronic Mail; Enrollment; Facebook; Focus Groups; Funding; Future; Goals; Government; HIV; HIV Vaccine Trials Network; HIV vaccine; Health; Health Services; Instagram; International; Interruption; Knowledge; Lesbian Gay Bisexual Transgender Queer; Longterm Follow-up; Marketing; Measures; Media Campaign; Medical Research; Misinformation; Modeling; Outcome; Participant; Patient Recruitments; Performance; Phase; Phase III Clinical Trials; Population Heterogeneity; Positioning Attribute; Preventive; Protocols documentation; Published Comment; Registries; Research; Research Personnel; Series; Surveys; Taxonomy; Testing; Time; Training; Trust; Twitter; United States; Vaccine Clinical Trial; Vaccines; Visit; Work; clinical research site; clinical training; combat; community based participatory research; community engagement; community partnership; design; early phase trial; efficacy testing; eligible participant; equity, diversity, and inclusion; evidence base; experience; forging; health communication; implementation research; improved; innovation; marginalized community; multidisciplinary; outreach; participant enrollment; primary outcome; programs; recruit; seropositive; social media; social stigma; trend analysis; trial enrollment; trustworthiness; vaccine hesitancy; vaccine trial; virtual; web site

Project Summary/Abstract The HIV Vaccine Trials Network (HVTN) has experienced significant challenges recruiting participants in early-stage HIV vaccine clinical trials. Formidable barriers to participation in HVTN preventive HIV early phase trials, including lack of HIV public urgency, numerous study visits, long-term follow-up, vaccine induced seropositivity and HIV stigma, have resulted in significant challenges enrolling participants into these trials. We will co-refine an existing media campaign, develop, test and evaluate a multilevel communication strategy to address some of these crucial concerns and strengthen our reputation of trustworthiness in marginalized communities disproportionately affected by HIV to increase their enrollment into early-stage HIV vaccine trials. Over the next 7 years, the HVTN will focus on the early phase trial program to move the field forward and to identify products efficiently and effectively for later efficacy testing. This will require the development and deployment of evidence-based strategies to combat misinformation and to strengthen community engagement. Our team and the clinical research sites in our Network have forged longstanding community partnerships with diverse stakeholders. During our phase 3 clinical trials for the US government-funded COVID-19 vaccine clinical trials we developed new strategies to supplement our community engagement program: (1) a consumer-driven marketing and advertising campaign; (2) virtual town halls and listening sessions; and (3) the use of expert panels to review protocols and provide guidance and direction. We will build on this work to inform our HIV strategy. We assembled an experienced team of diverse researchers to accomplish the following aims: 1) Identify components of an initial media campaign that impact HIV vaccine trial registration and develop a multilevel communication strategy; 2) Evaluate the impact of the multilevel communication strategy on Phase I HIV vaccine trial registration; and 3) Determine if the multilevel communication strategy generates public engagement with vaccines and vaccine trials. This project will be the first large-scale communication study conducted in the United States to improve community awareness of and engagement with HIV vaccine trial research. It will assess misinformation and engagement with this strategy to inform current and future HIV vaccine trials recruitment and is expected to have a positive health impact by establishing robust strategies to improve diversity, equity, and inclusion in Phase 1 preventive HIV vaccine trials.

项目摘要/摘要 HIV疫苗试验网络（HVTN）遇到了重大挑战 早期HIV疫苗临床试验的参与者。强大的参与障碍 在HVTN预防性HIV早期试验中，包括缺乏艾滋病毒公众紧迫性，许多 研究就诊，长期随访，疫苗诱导的血清阳性和HIV污名具有 导致参与者参加这些试验的重大挑战。我们将共同进行 现有的媒体活动，开发，测试和评估多层次交流 解决其中一些关键问题并加强我们的声誉的策略 边缘化社区的可信赖性不成比例地受到艾滋病毒影响 增加他们参加早期艾滋病毒疫苗试验的入学率。在接下来的7年中， HVTN将重点介绍早期试验计划，以推动该领域向前发展并确定 产品有效，有效地进行疗效测试。这将需要 制定和部署基于证据的策略，以打击错误信息和 加强社区参与。我们的团队和我们的临床研究网站 网络已经与各种利益相关者建立了长期的社区伙伴关系。 在我们的第3阶段临床试验中，美国政府资助的Covid-19疫苗临床 试验我们制定了新的策略来补充我们的社区参与计划： （1）由消费者驱动的营销和广告活动； （2）虚拟市政厅和 聆听会议； （3）使用专家面板来审查协议并提供 指导和指导。我们将以这项工作为基础，以告知我们的艾滋病毒策略。我们 组建了一支经验丰富的研究人员团队，以实现以下目标： 1）确定影响HIV疫苗试验的初始媒体活动的组成部分 注册和制定多层次交流策略； 2）评估 I期HIV疫苗试验注册上的多层次通信策略； 3） 确定多层次通信策略是否会引起公众参与 疫苗和疫苗试验。该项目将是第一个大规模的通信研究 在美国进行，以提高社区对参与的认识和参与 与HIV疫苗试验研究。它将评估错误的信息和参与 为当前和未来的HIV疫苗试验招聘提供信息的策略，并有望 通过建立强大的策略来改善多样性，从而产生积极的健康影响， 公平性和纳入1期预防性HIV疫苗试验。